Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine 5% Spray for Lifelong Premature Ejaculation
NCT04062357Phase 2Completed
- Sponsor
- Sohag University
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lidocaine 10% oropharyngeal spray in premature ejaculation (PE) (2 arms), sponsored by Sohag University. Primary endpoints: Arabic Index of Premature Ejaculation Scores and Intravaginal Ejaculatory Latency Time. Started Apr 2018; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT04062357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062357.